Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients

Journal of Psychiatric Practice

Volumn 15, Issue 2, 2009, Pages 150-153

  Coley, Kim C ^a   Scipio, Tina M ^a   Ruby, Christine ^a   Lenze, Eric J ^b   Fabian, Tanya J ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Activation; Agitation; Antipsychotic medications; Aripiprazole; Elderly; Side effects

Indexed keywords

ARIPIPRAZOLE;

AGED; AGITATION; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG SAFETY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MENTAL PATIENT; PRESCRIPTION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; AGING; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INPATIENTS; MALE; MENTAL DISORDERS; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; QUINOLONES; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 67650353995     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000348369.19172.ba     Document Type: Article

References (10)

1. Alexopoulos GS, Streim JE, Carpenter D. Expert consensus guidelines for using antipsychotic agents in older patients. J Clin Psychiatry 2004;65:100-2.
2. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302: 381-9.
3. Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441:137-40.
4. Newcomer JW, Campos JA, Marcus RN, et al. A multicenter, randomized, double-blind study of the effects of aripiprazole in overweight subjects with schizophrenia or schizoaffective disorder switched from olanzapine. J Clin Psychiatry 2008;69:1046-56.
5. van Winkel R, De Hert M, Wampers M, et al. Major changes in glucose metabolism, including new onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2008;69:472-9.
6. Abilify® (aripiprazole). Package insert. Otsuka Pharmaceutical Co., Ltd., June 2006.
7. Coley KC, DaPos SV, Saul MI, et al. Outcomes assessment in routine practice: Use of an electronic medical records database. Formulary 1999;34:52-7.
8. Centorrino F, Fogarty KV, Cimbolli P, et al. Aripiprazole: Initial clinical experience with 142 hospitalized psychiatric patients. J Psychiatr Pract 2006;11:241-7.
9. Marder SR, McQuade RD, Stock E, et al. Aripiprazole in the treatment of schizophrenia: Safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61: 23-36.
10. McEvoy JP, Daniel DG, Carson WH, et al. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15, or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007;41:895-905.